REPORT

Autonomic dysfunction is a major feature of cerebellar ataxia, neuropathy, vestibular areflexia ‘CANVAS’ syndrome

Teddy Y. Wu,1 Jennifer M. Taylor,2 Dean H. Kilfoyle,1,3 Andrew D. Smith,4 Ben J. McGuinness,4 Mark P. Simpson,1,3 Elizabeth B. Walker,1,3 Peter S. Bergin,1,3 James C. Cleland,1,3 David O. Hutchinson,1,3 Neil E. Anderson,1,3 Barry J. Snow,1,3 Tim J. Anderson,5,6 Laura A.F. Paermentier,6 Nick J. Cutfield,7 Andrew M. Chancellor,8 Stuart S. Mossman2 and Richard H. Roxburgh1,3

1 Department of Neurology, Auckland City Hospital, 2 Park Road, Auckland 1023, New Zealand
2 Department of Neurology, Wellington Hospital, Riddiford Street, Wellington 6021, New Zealand
3 Centre for Brain Research, University of Auckland, 85 Park Road, Auckland 1142, New Zealand
4 Department of Radiology, Auckland City Hospital, 2 Park Road, Auckland 1023, New Zealand
5 Department of Medicine, University of Otago, Christchurch, 2 Riccarton Avenue, Christchurch 8140, New Zealand
6 New Zealand Brain Research Institute, 66 Stewart Street, Christchurch 8011, New Zealand
7 Department of Medicine and Brain Health Research Centre, University of Otago, Dunedin, PO Box 56, Dunedin 9054, New Zealand
8 Department of Neurology, Tauranga Hospital, 829 Cameron Road, Tauranga 3112, New Zealand

Correspondence to: Dr Richard Roxburgh,
Centre for Brain Research,
University of Auckland, Auckland 1142, New Zealand
E-mail: richardr@adhb.govt.nz

Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) is a recently recognized neurodegenerative ganglionopathy. Prompted by the presence of symptomatic postural hypotension in two patients with CANVAS, we hypothesized that autonomic dysfunction may be an associated feature of the syndrome. We assessed symptoms of autonomic dysfunction and performed autonomic nervous system testing among 26 patients from New Zealand. After excluding three patients with diabetes mellitus, 83% had evidence of autonomic dysfunction; all patients had at least one autonomic symptom and 91% had more than two symptoms. We also found a higher rate of downbeat nystagmus (65%) than previously described in CANVAS. We confirmed that sensory findings on nerve conduction tests were consistent with a sensory ganglionopathy and describe two patients with loss of trigeminal sensation consistent with previous pathological descriptions of trigeminal sensory ganglionopathy. Our results suggest that autonomic dysfunction is a major feature of CANVAS. This has implications for the management of patients with CANVAS as the autonomic symptoms may be amenable to treatment. The findings also provide an important differential diagnosis from multiple system atrophy for patients who present with ataxia and autonomic failure.

Keywords: CANVAS syndrome; cerebellar ataxia; vestibular failure; neuronopathy; autonomic failure

Abbreviations: CANVAS = cerebellar ataxia, neuropathy, vestibular areflexia syndrome; SAS = Survey of Autonomic Symptoms; TIS = Total Symptom Impact Score

Received March 25, 2014. Revised May 21, 2014. Accepted June 10, 2014.
© The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com
Introduction

In 1995, Rinne et al. reported the association of a progressive cerebellar disorder in 7 of 53 patients with bilateral vestibular failure; four of these patients also had sensory neuropathy. The co-occurrence of ataxia, vestibular failure and neuropathy has since been described in several cohorts (Migliaccio et al., 2004; Zingler et al., 2007; Wagner et al., 2008; Kirchner et al., 2011; Szmulewicz et al., 2011, 2014). Szmulewicz et al. (2011) coined the term CANVAS (Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome). They subsequently reported post-mortem histopathological findings in three patients: cerebellar atrophy, predominantly affecting the superior and inferior vermic and Purkinje cell layers with preservation of the brainstem neurons; atrophy of the vestibular, geniculate and trigeminal ganglia; and atrophy of the sensory ganglia and dorsal columns (Szmulewicz et al., 2014). The latter finding is consistent with the neuropathological finding of complete loss of sensory action potentials rather than a length-dependent pattern of sensory loss.

In 2012, two of our patients with CANVAS were noted to have symptomatic postural hypotension. The combination of postural hypotension and progressive ataxia suggested that their diagnosis might have been multiple system atrophy, but the prolonged clinical course, absence of rapid eye movement sleep behaviour disorder, parkinsonism or brainstem atrophy on MRI, and the presence of vestibular failure were against this diagnosis.

We hypothesized that autonomic failure may be a feature of CANVAS itself and tested this hypothesis by assessing autonomic function in as many patients with CANVAS as we could identify. We also attempted to elucidate the neuroanatomical basis for downbeat nystagmus (Supplementary material).

Materials and methods

Patients

Neurologists throughout New Zealand were approached for patients diagnosed with CANVAS. The histories and examination findings were established retrospectively for each patient using hospital notes, supplemented where necessary with additional assessments by the authors. To fulfil the diagnosis of CANVAS patients had progressive cerebellar ataxia, bilateral vestibular failure and sensory neuropathy/neuropathy without another cause for symptoms such as alcoholic cerebellar degeneration or aminoglycoside toxicity.

Vestibular failure had initially been diagnosed in all patients with a positive head impulse test (Weber et al., 2008). Where available, vestibular failure was confirmed either by quantitative vestibulo-ocular reflex on video-oculography (Supplementary material) or caloric testing (Kim et al., 2011), to avoid including patients with false positive head impulse test (Kremmyda et al., 2012). Where quantitative testing was not available, vestibular failure was qualitatively confirmed if there was an impaired visually enhanced vestibulo-ocular reflex on video-oculography (Petersen et al., 2013). Where no confirmatory laboratory test was available (two patients) the head impulse test was required to be unequivocally positive. Neuropathy was considered to be present when nerve conduction studies demonstrated reduced or absent sensory nerve action potentials.

Imaging analysis

All patients had had MRIs. The images were reviewed by two experienced neuroradiologists to exclude other causes of ataxia and to compare the appearances with those previously described in CANVAS. In addition, the images were analysed for regional cerebellar atrophy, in an attempt to localize an anatomical correlate of downbeat nystagmus (Supplementary material and Supplementary Fig. 1).

Autonomic assessment

Autonomic assessment was performed prospectively using the same protocol in each centre. The Survey of Autonomic Symptoms (SAS) devised by Zilliox et al. (2011) was administered to all patients. The SAS is a questionnaire comprising 11 (for females) or 12 (for males) items, validated for assessing autonomic symptoms in patients with autonomic neuropathy. The Total Symptom Impact Score (TIS) derived by summing the rated severity of individual SAS scores was calculated. Results were compared with the published distribution of results in patients with and without neuropathy (Zilliox et al., 2011).

Bedside cardiac autonomic tests were performed using the protocol developed for the diagnosis of diabetic autonomic neuropathy (Ewing and Clarke, 1982; Ewing et al., 1985). Parasympathetic function was assessed by continuous ECG monitoring for heart rate variation during Valsalva manoeuvre, deep breathing and on standing. Sympathetic function was assessed by measuring blood pressure response to change in posture and handgrip. Each autonomic test (except the Valsalva ratio) has a defined normal, borderline and abnormal range (Ewing et al., 1985). Assigning 0 for normal, 1 for borderline and 2 for abnormal, and with minor modification to the Ewing classification, we defined definite parasympathetic dysfunction as a score ≥4 and definite sympathetic dysfunction as a score ≥2. Details of the autonomic function test protocol are provided in the Supplementary material.

Ethics approval

The study was conducted in accordance with the Declaration of Helsinki and approved online by the New Zealand Health and Disability Ethics Committee. All patients gave written consent for their data to be published in this manner.

Statistics

The data are described with standard descriptive statistics. Pearson’s test was used to test potential correlations of autonomic symptom scores and autonomic function test subscores. Statistical analysis was performed using R version 3.01 (http://www.R-project.org/).

Results

Twenty-six patients with CANVAS were recruited from seven centres; Auckland, n = 13; Wellington, n = 6; Christchurch and Tauranga, n = 2 each; Dunedin, Hamilton and Whangarei, n = 1 each. The mean age at assessment was 65.8 years (range 49–84); mean age of symptom onset was 54.6 years (range 19–82) and mean duration of symptoms was 11.7 years (range 1–35). Two-thirds of the patients were female (Table 1). All patients had European ancestry; four also had New Zealand Maori ancestry and two had other Polynesian ancestry. Most patients (22/26) reported gait imbalance as their initial symptom; three presented with sensory symptoms in the distal extremities. Two patients
Table 1 Summary of patient characteristics and results of autonomic evaluation

<table>
<thead>
<tr>
<th>Age</th>
<th>Gender</th>
<th>Duration of symptoms</th>
<th>MRI findings</th>
<th>Diagnosis of CANVAS</th>
<th>Nystagmus</th>
<th>Vestibular failure: Gains R, L</th>
<th>Autonomic symptom assessment</th>
<th>Sympathetic dysfunction</th>
<th>Para-sympathetic dysfunction</th>
<th>Valsalva response to standing (30:15 ratio)</th>
</tr>
</thead>
<tbody>
<tr>
<td>75</td>
<td>Female</td>
<td>Sensory alteration legs 12 years</td>
<td>2013 Moderate vermis atrophy M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2013 Absent SNAPs (arm + leg). Normal Motor study</td>
<td>Quantitative VOR 0.20, 0.12</td>
<td>Downbeat</td>
<td>2 2 42 4 4.7 1.09 1.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>Female</td>
<td>Gait ataxia 23 years</td>
<td>2010 Moderate vermis atrophy. M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2013 Absent SNAPs Reduced CMAPs, increased distal latency</td>
<td>Quantitative VOR 0.06, 0.04</td>
<td>Downbeat, rotatory</td>
<td>8 21 +2 5 30.7 1.97 1.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>Male</td>
<td>Gait ataxia 15 years</td>
<td>2010 Moderate dorsal and severe vermis atrophy. Severe M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2013 Absent SNAPs arms/legs. Normal motor study</td>
<td>Quantitative VOR 0.31, 0.38</td>
<td>No</td>
<td>6 18 30 6 7.2 1.09 1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Male</td>
<td>Gait ataxia 21 years</td>
<td>2011 Severe vermis atrophy. Severe M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2011 Absent SNAPs. Mild widespread motor neuropathy</td>
<td>Quantitative VOR 0.07, 0.10</td>
<td>Downbeat</td>
<td>4 8 +6 12 9.2 1.18 1.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>Female</td>
<td>Gait ataxia 13 years</td>
<td>2009 Moderate ventral and severe vermis atrophy. Moderate M. Crus I atrophy</td>
<td>Gait ataxia, dysarthria</td>
<td>2013 Absent SNAPs. Normal Motor study</td>
<td>Quantitative VOR 0.19, 0.11</td>
<td>Gaze evoked horizontal nystagmus</td>
<td>5 8 8 8 32.3 1.72 1.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>Male</td>
<td>Gait ataxia 7 years</td>
<td>2012 Moderate vermis atrophy. Moderate M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2012 Absent SNAPs. Normal Motor study</td>
<td>Quantitative VOR 0.21, 0.21</td>
<td>Gaze evoked nystagmus</td>
<td>3 7 36 7 24.1 1.37 1.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>76</td>
<td>Male</td>
<td>Gait ataxia, sensory loss legs 4 years</td>
<td>2010 M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2011 Absent SNAPs. Normal Motor study</td>
<td>Quantitative VOR 0.23, 0.11</td>
<td>Downbeat</td>
<td>2 4 53 9 15.4 1.19 1.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>Female</td>
<td>Gait ataxia 9 years</td>
<td>2013 Mild ventral and dorsal vermis atrophy. Mild M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2012 Absent SNAPs. Normal Motor study</td>
<td>Quantitative VOR 0.16, 0.15</td>
<td>Gaze evoked horizontal nystagmus</td>
<td>4 8 10 7 3.6 1.39 1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Male</td>
<td>Gait ataxia and numbness feet 1 year</td>
<td>2013 Mild ventral vermis atrophy. Mild M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2013 Absent SNAPs. Normal Motor study</td>
<td>Quantitative VOR 0.22, 0.21</td>
<td>Downbeat</td>
<td>1 2 +4 18 11.1 1.07 ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>Female</td>
<td>Gait ataxia 13 years</td>
<td>2004 Mild ventral vermis atrophy. Moderate M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2003 Absent SNAPs. Normal Motor study</td>
<td>Quantitative VOR 0.99, 0.57 Dynamic VA</td>
<td>Downbeat</td>
<td>5 10 65 5 11.2 1.24 1.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>Female</td>
<td>Gait ataxia 10 years</td>
<td>2013 Mild vermis and M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2004 Absent SNAPs. Normal Motor study</td>
<td>Quantitative VOR 0.03, 0.34</td>
<td>Downbeat</td>
<td>4 12 41 5 12.4 1.45 1.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Female</td>
<td>Gait ataxia 5 years</td>
<td>2011 Mild dorsal atrophy. Mild M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2011 Absent SNAPs Normal motor study</td>
<td>Quantitative VOR 0.97, 0.90</td>
<td>None</td>
<td>5 15 24 7 5.0 1.07 1.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td>Female</td>
<td>Gait ataxia 24 years</td>
<td>2000 Mild dorsal and moderate vermis atrophy. Mild M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2000 Absent SNAPs Normal motor study</td>
<td>Quantitative VOR 0.11, 0.30 Calorics</td>
<td>Dynamic VA</td>
<td>6 14 5 2 NR 1.92 1.43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Female</td>
<td>Gait ataxia 5 years</td>
<td>2008 Mild ventral vermis atrophy. Mild M. Crus I atrophy</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>2009 Absent or reduced SNAPs. Normal motor study</td>
<td>Calorics, Dynamic VA</td>
<td>Downbeat</td>
<td>6 9 3 3 8.0 1.29 1.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Female</td>
<td>Gait ataxia, ‘pas tic gait’ 35 years</td>
<td>1998 Normal</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>1999 (age 39) Low sural SNAPs, normal motor and sensory studies elsewhere</td>
<td>Calorics, Dynamic VA</td>
<td>Downbeat, horizontal</td>
<td>10 27 +12 15 16.5 1.28 1.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Age</th>
<th>Gender</th>
<th>First symptom at onset</th>
<th>Duration of symptoms</th>
<th>MRI findings</th>
<th>Diagnosis of CANVAS</th>
<th>Nystagmus</th>
<th>Autonomic symptom assessment</th>
<th>Sympathetic dysfunction</th>
<th>Para-sympathetic dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>17+</td>
<td>76</td>
<td>Female</td>
<td>Gait ataxia</td>
<td>17 years</td>
<td>1999</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>Quantitative VOR 0.12, 0.24</td>
<td>Downbeat, horizontal</td>
<td>+5 34</td>
</tr>
<tr>
<td>18+</td>
<td>63</td>
<td>Female</td>
<td>Gait ataxia</td>
<td>15 years</td>
<td>2011</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>Quantitative VOR 0.09, 0.03</td>
<td>Horizontal</td>
<td>4 2</td>
</tr>
<tr>
<td>19S</td>
<td>69</td>
<td>Female</td>
<td>Gait ataxia</td>
<td>17 years</td>
<td>2006</td>
<td>Gait ataxia, dysarthria</td>
<td>Quantitative VOR 0.50, 0.50</td>
<td>Calorics Dynamic VA</td>
<td>1 1</td>
</tr>
<tr>
<td>20</td>
<td>68</td>
<td>Female</td>
<td>Paraesthesia limbs, mild ataxia</td>
<td>2.5 yr</td>
<td>2011</td>
<td>Gait ataxia, limb ataxia</td>
<td>Quantitative VOR 0.50, 0.50</td>
<td>Gaze evoked horizontal nystagmus</td>
<td>7 23</td>
</tr>
<tr>
<td>21</td>
<td>71</td>
<td>Male</td>
<td>Paraesthesia limbs</td>
<td>8 yrs</td>
<td>2011</td>
<td>Moderate ventral vermian atrophy</td>
<td>Calorics VVOR</td>
<td>Downbeat</td>
<td>5 14</td>
</tr>
<tr>
<td>22*</td>
<td>53</td>
<td>Female</td>
<td>Gait ataxia</td>
<td>12 years</td>
<td>2006</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>Vestibulo-oculargraphic VVOR</td>
<td>Downbeat</td>
<td>5 17</td>
</tr>
<tr>
<td>23</td>
<td>52</td>
<td>Male</td>
<td>Gait ataxia</td>
<td>5 years</td>
<td>2012</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>Vestibulo-oculargraphic VVOR</td>
<td>Downbeat</td>
<td>4 5</td>
</tr>
<tr>
<td>24</td>
<td>84</td>
<td>Male</td>
<td>Gait ataxia</td>
<td>1.5 years</td>
<td>2013</td>
<td>Global cerebellar atrophy</td>
<td>Quantitative VOR 0.23, 0.28</td>
<td>Downbeat</td>
<td>6 14</td>
</tr>
<tr>
<td>25</td>
<td>49</td>
<td>Female</td>
<td>Chronic cough</td>
<td>7 years</td>
<td>2011</td>
<td>Gait ataxia, limb ataxia, dysarthria</td>
<td>Quantitative VOR 0.38, 0.38</td>
<td>Downbeat</td>
<td>4 10</td>
</tr>
<tr>
<td>26</td>
<td>73</td>
<td>Female</td>
<td>Gait ataxia</td>
<td>4 years</td>
<td>2013</td>
<td>Gait ataxia, limb ataxia</td>
<td>Head Impulse Test</td>
<td>Downbeat</td>
<td>6 16</td>
</tr>
</tbody>
</table>

*, **, #, + denote sibling pairs.
$ part of sibling pair but sister is deceased.
Gains = ratio of (velocity of eye movement)/(velocity of head movement) 80ms after onset of head impulse.
Interpretation of autonomic test results adapted from Ewing et al. (1985). Valsalva ratio: normal ≥ 1.22, abnormal ≤ 1.21.
Heart rate variation during deep breathing: normal ≥ 15, borderline 11-14, abnormal ≤ 10.
Heart rate response to standing (30:15 ratio): normal ≥ 1.04, borderline 1.01-1.03, abnormal ≤ 1.0.
Postural systolic blood pressure decline: normal <10mmHg, borderline 11-29mmHg, abnormal ≥30mmHg.
Diastolic blood pressure response to sustained handgrip: normal ≥16mmHg, borderline 11-15mmHg, abnormal ≤10mmHg.
In bold = abnormal; underlined = borderline, otherwise normal.
DBP = diastolic blood pressure; ND = not done; NR = no result (Patient 14 had frequent atrial ectopics. Patients 19 and 26 had frequent pauses during this part of the test to render result uninterpretable); SBP = systolic blood pressure; SNAP = sensory nerve action potential; VOR = vestibulo-ocular reflex; VVOR = visually enhanced vestibulo-ocular reflex; R = right, L = left; NCS = nerve conduction studies; HR = heart rate; CMAP = compound muscle action potential; VA = visual acuity.
described chronic cough and in one patient this was the initial symptom, 5 years before the onset of ataxia. On examination, all had gait ataxia whereas 23 (88%) patients also had dysarthria and/or limb ataxia. Twenty-four (92%) had nystagmus, 17 of whom (65%) had downbeat nystagmus. Two patients had absent pinprick appreciation on the face. Three patients had diabetes mellitus; we excluded their autonomic assessments from our analysis.

In 22 subjects, the presence of bilateral vestibular failure was confirmed by quantitative testing: 18 subjects by quantitative video-oculographic head impulse testing, and four by bithermal caloric tests. The diagnosis was confirmed with abnormal visually enhanced vestibulo-ocular reflex tests recorded with video-oculography in two patients; only two subjects were diagnosed on the basis of bilateral unequivocally positive clinical head impulse tests.

The degree of vestibular failure was marked with the average gain on video-oculography being 0.24 [standard deviation (SD) 0.16, range 0.03–0.57, normal >0.79]. The results for both sides were similar within an individual, the average absolute difference in gain between the two sides being 0.07 (correlation coefficient 0.8, \(P = 0.0001\)).

The pattern of the nerve conduction tests pointed to a sensory neuropathy with absent sensory action potentials in 21 of the 23 (91%) non-diabetic patients.

**Figure 1** Distribution of autonomic function test scores. The dark grey shaded area represents abnormal results, light grey represents borderline results and pale grey represents normal results. The dashed line represents mean normal values derived from Ewing et al. (1985). The solid red line represents the median test value. (A) The three parasympathetic test results; and (B) the two sympathetic test results. Insp-Exp = inspiration-expiration; HR = heart rate; BP = blood pressure.
Genetic and vitamin E testing

Eighteen patients had been tested for spinocerebellar ataxia 1, 2, 3, 6 and 7; nine of these had also been tested for spinocerebellar ataxia 17; five for dentatorubral-pallidolysian atrophy and two for SPG7, which has been described in a patient with ataxia and vestibular failure (Roxburgh et al., 2013). Serum vitamin E levels had been measured in 13 patients, all results were normal.

Brain imaging

Of the 25 MRI scans available for review, two were normal, one showed generalized cerebellar atrophy and 22 had some degree of vermis and crus I atrophy as previously described in CANVAS (Szmulewicz et al., 2011). No patient had brainstem or upper cervical cord atrophy. Twenty-three scans were available for assessment of focal atrophy. Crus I atrophy was associated with increased disease duration (P < 0.001) but not with patient age. No specific association with downbeat nystagmus was found (Supplementary material).

Survey of autonomic symptoms

All patients reported at least one SAS autonomic symptom and 21 patients (91%) reported at least two (Table 2). The median SAS score was 4 (range 1–10). The median TIS score was 9 (range 1–27). The distribution of these scores was significantly different from the historical controls [SAS 95% confidence interval (CI): 0.58–1.69, TIS 95% CI: 1.51–5.02] (Zilliox et al., 2011). Cold feet (78%), light-headedness (65%), constipation (65%) and dry mouth or eyes (52%) were the most common symptoms. Additionally, 78% (seven of nine) of the males had erectile dysfunction. Symptom severity was similar to that reported in patients with diabetic autonomic neuropathy (Fig. 2B) (Zilliox et al., 2011).

There was a modest linear correlation of increasing SAS (rho = 0.41) and TIS (rho = 0.48) scores with disease duration (P = 0.04 and 0.02, respectively) but not with age (Fig. 2).

Autonomic function results

Parasympathetic testing

An abnormal heart rate response to deep breathing was noted in 10 (48%) patients, and to standing in 8 patients (36%). Valsalva ratio was abnormal in 9 patients (41%). Nine (39%) patients had definite parasympathetic dysfunction, as defined by our pre-specified criteria (Fig. 1A).

Sympathetic testing

Seventeen (77%) patients had an abnormal diastolic response to handgrip and seven (30%) patients had orthostatic hypotension. Eighteen (78%) patients had definite sympathetic dysfunction (Fig. 1B). Nineteen (83%) patients had either definitely abnormal parasympathetic or sympathetic function, or both. There was no clear correlation between the two in individual patients. There was no correlation between the individual autonomic test results and either disease duration or increasing age. At the time of the autonomic tests, two patients were taking a beta-blocker; one of these patients had abnormal diastolic blood pressure response to handgrip, and the other had two abnormal parasympathetic and one borderline sympathetic tests.

Discussion

This is the first report to document autonomic symptoms and autonomic function in a large cohort of patients with CANVAS. We have demonstrated a high prevalence of autonomic dysfunction, confirming our hypothesis that autonomic failure is an important feature of this condition. This is consistent with a recent report of a sibling pair of patients with CANVAS who had histopathological evidence of sweat gland denervation (Umeh et al., 2013).

The major differential diagnosis in a patient with progressive ataxia and autonomic dysfunction is multiple system atrophy (Wenning et al., 1994), and indeed two of our patients had been incorrectly diagnosed with multiple system atrophy. There are several important features that distinguish CANVAS from multiple system atrophy. Bilateral vestibulopathy rarely, if ever, occurs in multiple system atrophy. Anderson et al. (2008) reported bilaterally impaired vestibular function in just 1 of 30 patients with probable multiple system atrophy. The authors considered that this patient may have had another diagnosis and we postulate that the patient in fact, had CANVAS. Furthermore, in another series of 255 patients with bilateral vestibular failure, just three patients were diagnosed with multiple system atrophy (Zingler et al., 2007). The non-length dependent sensory neuronopathy, characteristic of CANVAS, as confirmed in this study, is a second feature of the syndrome that distinguishes it from multiple system atrophy; although peripheral neuropathy has occasionally been described in patients with multiple system atrophy, this has been a predominantly motor axonopathy (Gawel et al., 2012). Downbeat nystagmus may also favour a diagnosis of CANVAS. Downbeat nystagmus has been reported in multiple system atrophy (Anderson et al., 2008), but in a series of 117 patients with downbeat nystagmus, only one patient had multiple system atrophy (Anderson et al., 2008).
atrophy (Wagner et al., 2008). In contrast, downbeat nystagmus was a common feature (65%) in our cohort, higher than the 28% observed by Szmulewicz et al. (2011). Long disease duration is another feature favouring CANVAS over multiple system atrophy. In our study, the median duration from first symptoms was 12 years, whereas the average time from first symptoms to death in multiple system atrophy is 9.3 years (Wenning et al., 1994). Conversely, there are features of multiple system atrophy that are not present in CANVAS: rapid eye movement sleep behaviour disorder, parkinsonism, and brainstem atrophy on MRI (Brooks et al., 2009). Our study confirmed that in CANVAS, MRI changes were confined to the cerebellum. Vermian and crus I atrophy increased with disease duration, supporting this as an integral feature of CANVAS.

The severity and range of autonomic symptoms and signs also differ between multiple system atrophy and CANVAS. In patients with multiple system atrophy assessed with Ewing’s protocol, postural hypotension (85%) was more common than abnormal diastolic blood pressure response to handgrip (38%) (Plaschke et al., 1998) whereas we found the reverse (30% and 77%, respectively). Urinary symptoms are more prevalent (up to 83%) and more bothersome in multiple system atrophy (Metzler et al., 2013) than in CANVAS (39%, low symptom impact score). Autonomic failure is a major cause of morbidity in multiple system atrophy (Lipp et al., 2009) whereas all but one of our patients remain ambulant and, even then, this was due to ataxia.

We hypothesize that autonomic dysfunction in CANVAS is part of a primary ganglionopathy involving the autonomic, vestibular, facial, trigeminal and sensory ganglia (Szmulewicz et al., 2014). Supportive evidence comes from the markedly reduced sweat gland nerve fibre density in the skin biopsies of two siblings with CANVAS (Umeh et al., 2013). This localizes the lesion at least to the ‘post-ganglionic’ autonomic nervous system, though not distinguishing between a lesion of the ganglion itself or the

Figure 2 The SAS (A) and TIS (B) for historical controls and patients with diabetic neuropathy from Zilliox et al. (2011) (blue) compared with CANVAS patients (red). The box represents 25th to 75th centiles, the median is the horizontal line within the box, the whisker with error bars extends to the 10th and 90th centiles and the dots are the outliers. Figures are adopted from Zilliox et al. (2011) with permission from the authors.
emanating unmyelinated axons. This is, potentially, a further differentiation from multiple system atrophy in which the autonomic dysfunction is preganglionic (Lipp et al., 2009).

CANVAS is reasonably common with 26 cases found in New Zealand (population 4.5 million) within 2 years of knowing that the condition existed. Thirteen patients were diagnosed in Auckland (population 1.5 million) giving a minimum prevalence of 0.87/100 000. It is likely that CANVAS is under-diagnosed in patients presenting with ataxia in whom vestibular function is not examined. Likewise it has been estimated that 30% of patients with ‘idiopathic’ bilateral vestibulopathy have CANVAS (Strupp et al., 2013), but the diagnosis might not be considered if ataxia and neuropathy are not deliberately sought and the clinical entity recognized.

The strength of our study is the prospective examination of autonomic function using validated autonomic assessments in a substantial cohort of CANVAS patients. We recognize the limitation of comparing autonomic assessments with historical controls, but the consistency of our results across the centres lends them credibility. While we are exposed to the inherent limitations of retrospective ascertainment of patient data to confirm the diagnosis, determine rate of downbeat nystagmus and perform imaging analysis, we are confident of the clinicians’ abilities to diagnose ataxia, and vestibular failure and neuropathy were verified with physiological testing in most patients.

We conclude that autonomic dysfunction is a central feature of CANVAS providing an important differential diagnosis to multiple system atrophy when encountering patients with combined ataxia and autonomic dysfunction. Downbeat nystagmus is also more common in CANVAS than previous reported and if present should prompt the clinician to look for the other features of CANVAS. Neurologists should be more aware of this syndrome as it is a relatively common cause of ataxia. A head impulse test should be a routine part of the examination of every patient presenting with ataxia.

Supplementary material

Supplementary material is available at Brain online.

References

Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491–8.